The tale of TILs in breast cancer : a report from the International Immuno-Oncology Biomarker Working Group

dc.contributor.authorEl Bairi, Khalid
dc.contributor.authorHaynes, Harry R.
dc.contributor.authorBlackley, Elizabeth
dc.contributor.authorFineberg, Susan
dc.contributor.authorShear, Jeffrey
dc.contributor.authorTurner, Sophia
dc.contributor.authorDe Freitas, Juliana Ribeiro
dc.contributor.authorSur, Daniel
dc.contributor.authorAmendola, Luis Claudio
dc.contributor.authorGharib, Masoumeh
dc.contributor.authorKallala, Amine
dc.contributor.authorArun, Indu
dc.contributor.authorAzmoudeh-Ardalan, Farid
dc.contributor.authorFujimoto, Luciana
dc.contributor.authorSua, Luz F.
dc.contributor.authorLiu, Shi-Wei
dc.contributor.authorLien, Huang-Chun
dc.contributor.authorKirtani, Pawan
dc.contributor.authorBalancin, Marcelo
dc.contributor.authorAttar, Hicham El
dc.contributor.authorGuleria, Prerna
dc.contributor.authorYang, Wenxian
dc.contributor.authorShash, Emad
dc.contributor.authorChen, I-Chun
dc.contributor.authorBautista, Veronica
dc.contributor.authorDo Prado Moura, Jose Fernando
dc.contributor.authorRapoport, Bernardo Leon
dc.contributor.authorCastaneda, Carlos
dc.contributor.authorSpengler, Eunice
dc.contributor.authorAcosta-Haab, Gabriela
dc.contributor.authorFrahm, Isabel
dc.contributor.authorSanchez, Joselyn
dc.contributor.authorCastillo, Miluska
dc.contributor.authorBouchmaa, Najat
dc.contributor.authorZin, Reena R. Md
dc.contributor.authorShui, Ruohong
dc.contributor.authorOnyuma, Timothy
dc.contributor.authorYang, Wentao
dc.contributor.authorHusain, Zaheed
dc.contributor.authorWillard-Gallo, Karen
dc.contributor.authorCoosemans, An
dc.contributor.authorPerez, Edith A.
dc.contributor.authorProvenzano, Elena
dc.contributor.authorEricsson, Paula Gonzalez
dc.contributor.authorRichardet, Eduardo
dc.contributor.authorMehrotra, Ravi
dc.contributor.authorSarancone, Sandra
dc.contributor.authorEhinger, Anna
dc.contributor.authorRimm, David L.
dc.contributor.authorBartlett, John M.S.
dc.contributor.authorViale, Giuseppe
dc.contributor.authorDenkert, Carsten
dc.contributor.authorHida, Akira I.
dc.contributor.authorSotiriou, Christos
dc.contributor.authorLoibl, Sibylle
dc.contributor.authorHewitt, Stephen M.
dc.contributor.authorBadve, Sunil
dc.contributor.authorSymmans, William Fraser
dc.contributor.authorKim, Rim S.
dc.contributor.authorPruneri, Giancarlo
dc.contributor.authorGoel, Shom
dc.contributor.authorFrancis, Prudence A.
dc.contributor.authorInurrigarro, Gloria
dc.contributor.authorYamaguchi, Rin
dc.contributor.authorGarcia-Rivello, Hernan
dc.contributor.authorHorlings, Hugo
dc.contributor.authorAfqir1, Said
dc.contributor.authorSalgado, Roberto
dc.contributor.authorAdams, Sylvia
dc.contributor.authorKok, Marleen
dc.contributor.authorVittoria Dieci, Maria
dc.contributor.authorMichiels, Stefan
dc.contributor.authorDemaria, Sandra
dc.contributor.authorLoi, Sherene
dc.date.accessioned2022-12-12T09:12:45Z
dc.date.available2022-12-12T09:12:45Z
dc.date.issued2021-12-01
dc.description.abstractThe advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed deathligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.en_US
dc.description.departmentImmunologyen_US
dc.description.librarianam2022en_US
dc.description.sponsorshipThe National Health and Medical Research Council of Australia; the Cure; the Royal Australasian College of Physicians; the NIH/NCI ; the National Breast Cancer Foundation of Australia Endowed Chair; the Breast Cancer Research Foundation, New York and the Breast Cancer Research Foundation (BCRF).en_US
dc.description.uriwww.nature.com/npjbcanceren_US
dc.identifier.citationBairi, K.E., Haynes, H.R., Blackley, E. et al. 2021, 'The tale of TILs in breast cancer : a report from the International Immuno-Oncology Biomarker Working Group', NPJ Breast Cancer, vol. 7, art.. 150, pp. 1-17, doi : 10.1038/s41523-021-00346-1.en_US
dc.identifier.issn2374-4677
dc.identifier.other10.1038/s41523-021-00346-1
dc.identifier.urihttps://repository.up.ac.za/handle/2263/88740
dc.language.isoenen_US
dc.publisherNature Researchen_US
dc.rights© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.subjectBreast canceren_US
dc.subjectPatienten_US
dc.subjectSurvivalen_US
dc.subjectImmune-checkpoint inhibitors (ICI)en_US
dc.subjectTumor-infiltrating lymphocytes (TILs)en_US
dc.titleThe tale of TILs in breast cancer : a report from the International Immuno-Oncology Biomarker Working Groupen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ElBairi_Tale_2021.pdf
Size:
2.1 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: